Thrombocytosis as a prognostic factor in women with cervical cancer

Lopes, Alberto; Daras, V.; Cross, Paul; Robertson, Greg; Beynon, Gareth; Monaghan, John M.

doi:10.1002/1097-0142(19940701)74:1<90::aid-cncr2820740116>3.0.co;2-0

Cited by 53 publications

(39 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, 14 studies (n =3490 patients) were eligible for the meta-analysis, and 12 of the 14 reports found an inverse relationship between 5-year overall survival and thrombocytosis, that is positive studies (Hernandez et al, 1992;Lopes et al, 1994;Rodriguez et al, 1994;Gücer et al, 1998;De Jonge et al, 1999;Scholz et al, 2000; Taucher et al, 2003;Li et al, 2004;Gorelick et al, 2009;Gungor et al, 2009;Lee et al, 2011;Qiu et al, 2012;Stone et al, 2012), leaving only 2 studies negative (Hernandez et al, 1994;Lavie et al, 1999).…”

Section: Eligible Studiessupporting

confidence: 80%

“…No significant publication biases were found in results of meta-analyses of thrombocytosis prediction value for 5-year overall survival (p=0.870; Figure 2).We analyzed the link between thrombocytosis and the prognosis of patients in stage Ⅰ to Ⅳ (Hernandez et al, 1994;Lopes et al, 1994;Gücer et al, 1998;Lavie et al, 1999;Hernandez et al, 2000;Gungor et al, 2009;Qiu et al, 2012;Stone et al, 2012), and found the mortality was 1.76-fold higher in patients with thrombocytosis (n=1974, RR=1.76, 95% CI= [1.19-2.62], p=0.005; Figure 3A). However, the patients in stage Ⅲ to Ⅳ did not have a higher mortality (Lopes et al, 1994;Scholz et al, 2000;Li et al, 2004;Gorelick et al, 2009;Lee et al, 2011) but a much lower (n=478, RR=1.29, 95% CI= [1.13-1.48], p=0.0003; Figure 3B). The result of studies (Hernandez et al, 1994;Lopes et al, 1994;Rodriguez et al, 1994;De Jonge et al, 1999) for relation of thrombocytosis and survival of patients in stage ⅠB cervical cancer was not far-off (n=1371, RR= 1.73, 95% CI= [1.71-2.58], p=0.007; Figure 4D).…”

Section: Meta-analysi: 5-year Overall Survivalmentioning

confidence: 99%

“…However, the patients in stage Ⅲ to Ⅳ did not have a higher mortality (Lopes et al, 1994;Scholz et al, 2000;Li et al, 2004;Gorelick et al, 2009;Lee et al, 2011) but a much lower (n=478, RR=1.29, 95% CI= [1.13-1.48], p=0.0003; Figure 3B). The result of studies (Hernandez et al, 1994;Lopes et al, 1994;Rodriguez et al, 1994;De Jonge et al, 1999) for relation of thrombocytosis and survival of patients in stage ⅠB cervical cancer was not far-off (n=1371, RR= 1.73, 95% CI= [1.71-2.58], p=0.007; Figure 4D). And unfortunately, we did not get enough data to evaluate the link between thrombocytosis and survival of patients in stage Ⅰ to Ⅱ.…”

Section: Meta-analysi: 5-year Overall Survivalmentioning

confidence: 99%

See 2 more Smart Citations

Pretreatment Thrombocytosis as a Prognostic Factor in Women with Gynecologic Malignancies: a Meta-analysis

Liu²,

Zhang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Eligible Studiessupporting

confidence: 80%

Section: Meta-analysi: 5-year Overall Survivalmentioning

confidence: 99%

Section: Meta-analysi: 5-year Overall Survivalmentioning

confidence: 99%

See 1 more Smart Citation

Pretreatment Thrombocytosis as a Prognostic Factor in Women with Gynecologic Malignancies: a Meta-analysis

Liu²,

Zhang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…However, its' prognostic importance have been observed frequently in patients with gynecological cancers, renal cell carcinoma, and lung cancer [21][22][23]. The prevalence of thrombocytosis in patients with gynecological cancer was 9.5-38%, 13-60% with primary lung cancer, 56.8% with renal cell carcinoma, and 33% with colon cancer [4,14,24,25].…”

Section: Discussionmentioning

confidence: 99%

The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment

et al. 2009

View full text Add to dashboard Cite

We aimed to investigate the prognostic significance of neutrophil, lymphocyte, platelet, mean platelet value (MPV), platelet-lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR) in patients with locally advanced gastric cancer (LAGC). One hundred sixty-eight patients with LAGC who had been followed-up between 2004 and 2008 were included in present study. The results of hematological (platelet, lymphocyte, neutrophil and MPV) and biochemical (uric acid and LDH) parameters were evaluated before treatment. NLR was divided into two groups as <2.56 and ≥2.57 and PLR was also divided into two groups as ≤160 and >160. Platelet counts and lymphocyte counts were also divided into two groups; ≤300.000/mm3 and >300.000/mm3, and <1,500/mm3 and ≥1,500/mm3, respectively. Results were evaluated with Kaplan-Meier and Long-rank tests. The mean age of patients at diagnosis was 60.1±12.1 and 114 of patients (67.8%) were male. For 168 patients, 48 months overall survival (OS) rate was 45.2% and the median OS was 39 months (range 33-44). In patients whose PLR was less than 160 (n=54), the median OS was 45 months (range 38-52) and also for cases whose PRL was greater than 160 (n=114), the median OS was 27 months (range 22-32) (p=0.006). While for fifty patients whose lymphocyte counts were less than 1,500, the median OS was 27 months (range 21-33), in cases with high lymphocyte counts (≥1,500) (n=118), it was 41 months (range 35-48) (p=0.03). The median OS was 41 (range 34-48) and 30 (range 23-37) months in two platelets groups, respectively (p=0.24). However, in the patients whose NLR was less than 2.56 (n=107), median OS was better than with cases whose NLR was greater than or equal to 2.56 (42 vs. 27 months). Routine peripheral blood counts may be useful prognostic factor for evaluating the accuracy of risk stratification in patients with radically resected gastric cancer Our results need to be confirmed by study including larger sample size in future.

show abstract

“…Elevated levels of platelet counts have been found to be a significant prognostic factor in carcinoma of the lung [12,28]. However, the association between thrombocytosis and survival has been questionable in multivariate analyses [8,11].…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of thrombocytosis in patients with primary lung cancer

Pedersen

Milman²

1996

Eur Respir J

190

View full text Add to dashboard Cite

In patients with malignancies, thrombocytosis has previously been related to disease stage, histological type, and survival. In the present study, the prevalence of thrombocytosis and the prognostic information provided by platelet counts were analysed in a large cohort of patients with primary lung cancer. At the time of diagnosis, pretreatment platelet counts were retrospectively recorded in 1,115 consecutive patients with histologically proven primary lung cancer. All patients were reviewed regarding histological type, tumour, node, metastasis (TNM) classification stage and survival. The prevalence of thrombocytosis in patients with lung cancer was compared with that in a series of 550 consecutive out-patients with benign lung disorders. In 269 surgically resected patients, postoperative platelet counts were recorded 1-3 months after resection of the tumour. In the follow-up period, thromboembolic episodes diagnosed either clinically or at autopsy were recorded. The overall prevalence of thrombocytosis (> 400 x 10(9) platelets.L-1) in the patients with lung cancer was 32%. The frequency of thrombocytosis was significantly higher compared with the control subjects (32 vs 6%; p < 0.0001). Platelet counts differed significantly among subgroups defined by the TNM classification, with the proportion of patients with > 400 x 10(9) platelets.L-1 greatest in the more advanced TNM stages (stage I and II 23% vs stage III and IV 37%; p < 0.0001). Patients with thrombocytosis had a significantly poorer survival than patients with normal platelet counts (p < 0.0001). In a multivariate survival analysis (Cox model), thrombocytosis continued to correlate strongly with poor survival even when adjusted for histological type, sex, age, and TNM stage (p < 0.001). In surgically resected patients, the frequency of preoperative and postoperative thrombocytosis differed significantly (23.0 vs 8.9%; p < 0.0001). Survival rate was significantly reduced in patients with preoperative thrombocytosis (p = 0.005). Thrombocytosis was not associated with an increased incidence of thromboembolism. In conclusion, thrombocytosis is an independent prognostic factor of survival in patients with primary lung cancer. We suggest that platelet counts should be included in future multivariate analyses of survival in patients with lung cancer.

show abstract

Thrombocytosis as a prognostic factor in women with cervical cancer

Cited by 53 publications

References 6 publications

Pretreatment Thrombocytosis as a Prognostic Factor in Women with Gynecologic Malignancies: a Meta-analysis

Pretreatment Thrombocytosis as a Prognostic Factor in Women with Gynecologic Malignancies: a Meta-analysis

The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment

Prognostic significance of thrombocytosis in patients with primary lung cancer

Contact Info

Product

Resources

About